CXCL17/VCC-1 Antibody [Alexa Fluor® 488]

• Applications: WB
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor 488

CXCL17/VCC-1 Antibody [Alexa Fluor® 488] Summary

• Immunogen: E. coli-derived recombinant mouse CXCL17/VCC‑1
  Ser31-Leu119
  Accession # Q5UW37
• Specificity: Detects mouse CXCL17/VCC‑1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 5% cross-reactivity with recombinant human CXCL17/VCC‑1 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Purity Statement: Antigen Affinity-purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

CXCL17, also known as dendritic cell and monocyte chemokine-like protein (DMC) and VEGF-correlated chemokine-1 (VCC-1), is a secreted molecule with a size and predicted three-dimensional folding pattern similar to that of chemokines CXCL8/IL-8 and CXCL14/BRAK (1, 2). It has no predicted N-glycosylation sites, so cleavage of a 22 amino acid (aa) signal sequence likely results in a mature mouse CXCL17 molecule of 97 aa and 11 kDa size. CXCL17 is constitutively produced by airway and intestinal epithelium (1). It induces the chemotaxis of quiescent, but not LPS‑activated peripheral blood monocytes and dendritic cells, and also binds these cells specifically (1). CXCL17 expression is increased in endothelial cells when they are induced to form tubes in vitro (2). Transgenic overexpression in NIH3T3 cells causes upregulation of proteins such as VEGF and FGF basic, and increases cell growth rate and tumorigenicity (2). CXCL17 and two other chemokines that play roles in angiogenesis, CXCL1/GRO and CXCL8/IL-8, show significantly correlated expression with that of VEGF in primary lung, breast and esophageal tumors (2). CXCL17 is therefore suggested to play a role in tumor angiogenesis. Mature mouse CXCL17 shares 82%, 71% and 66% amino acid sequence identity with rat, human and bovine CXCL17, respectively.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.